Skip to main content
All lobbying filings

AKIN GUMP STRAUSS HAUER & FELD

Lobbying for CHATTEM, INC. DBA OPELLA · Manufacturer of consumer healthcare products.

 Filing · LD-2 quarterly report Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 20, 2026
Income
$70,000
What the client paid this registrant for the period.
Client based in
New Jersey

Official filing document

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 1
Health Issues

Issues related to implementation of the OTC Drug Monograph User Fee Program reauthorization and non-prescription drug status, including Section 304 of H.R. 9393; issues related to consumer health care products supply chain; related FY27 appropriations report language, including Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 (H.R. 8646) and Financial Services and General Government Appropriations Act, 2027 (H.R. 8495); State of Men's Health Act (H.R. 7602, S. 5113); GRAS reform; CLEAR LABELS Act (S. 3788, H.R. 8269).

 Bills named in this filing 7
  • H.R. 9393
    Lower Costs, More Transparency Act of 2026
  • H.R. 8646
    Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027
  • H.R. 8495
    Financial Services and General Government Appropriations Act, 2027
  • H.R. 7602
    State of Men’s Health Act
  • S. 5113
    State of Men’s Health Act
  • S. 3788
    CLEAR LABELS Act
  • H.R. 8269
    CLEAR LABELS Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem